Newsletters

[Biomaterials] Scientists presented a polyelectrolyte multilayer-based surface coating designed to promote rapid spheroid formation from individual cancer cells.

[Proceedings of The National Academy of Sciences of The United States of America] While scientists showed a strong molecular resemblance between Aging-luminal progenitors (ALPs) in aged normal tissue and ALP-like cancer cells, proving that ALPs are the normal cell-of-origin of ALP-like tumors remains to be established by future lineage-tracing experiments.

[BMC Medicine] The expression of CSC markers CD44 and ALDH1A1 under treatment conditions was analyzed using immunohistochemistry and flow cytometry.

[Journal of the American College of Surgeons] Activating Notch1 signaling in melanoma-associated fibroblasts overcomes BRAF inhibitor resistance by disrupting cancer stem cell niches.

[Oncogenesis] Researchers revealed a novel HPV16 E7-APC2-SPIN4 axis as a key driver of cervical cancer. In this pathway, APC2 unexpectedly functions as an oncogene by activating the Wnt/β-catenin signaling to promote tumorigenesis and CSC properties.

[Molecular Carcinogenesis] Based on preliminary investigation, which showed that miR-203a was downregulated in ovarian CSCs and was subsequently activated by treatment with SFRP4 micropeptides, scientists investigated whether miR-203a plays any part in SFRP4 micropeptide-mediated ovarian CSC inhibition in PA-1 and SKOV-3 cell lines.

[Clinical and Experimental Medicine] Samples of thirteen breast cancers of unknown primarys and five known metastatic breast cancers were subjected to gene expression analysis. The identified CSC phenotype induced by the overexpression of T cell leukemia/lymphoma-1 A was validated via cytological experiments.

[Scientific Reports] Investigators used an enrichment method based on recombinant Plasmodium falciparum VAR2CSA protein to enable the capture of rare circulating tumor cells from a single blood draw in early-stage melanoma patients.

[Anticancer Research] Researchers elucidated the molecular mechanisms underlying CSC resistance to PAM-induced oxidative stress in non-small cell lung cancer.

[Genes & Diseases] The authors comprehensively address the recent findings of previous studies on the dysregulated roles of pseudogene-derived lncRNAs in directing and generating CSCs in various cancers.

[Certara, Inc.] Certara, Inc. announced its Simcyp^® Simulator enabled physiologically-based pharmacokinetic modeling predictions accepted by the US FDA in lieu of clinical studies to support the new drug application for asciminib.

[Blackstone Life Sciences] Blackstone Life Sciences announced a research and development funding agreement to advance the clinical development of bleximenib (JNJ-75276617), an investigational oral menin inhibitor, for AML.